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The present article describes the ﬁrst patient with a deﬁciency of ribose-5-phosphate isomerase (RPI) (Enzyme
Commission number 5.3.1.6) who presented with leukoencephalopathy and peripheral neuropathy. Protonmagnetic
resonance spectroscopy of the brain revealed highly elevated levels of the polyols ribitol and D-arabitol, which
were subsequently also found in high concentrations in body ﬂuids. Deﬁcient activity of RPI, one of the pentose-
phosphate-pathway (PPP) enzymes, was demonstrated in ﬁbroblasts. RPI gene–sequence analysis revealed a frame-
shift and a missense mutation. Recently, we described a patient with liver cirrhosis and abnormal polyol levels in
body ﬂuids, related to a deﬁciency of transaldolase, another enzyme in the PPP. RPI is the second known inborn
error in the reversible phase of the PPP, conﬁrming that defects in pentose and polyol metabolism constitute a new
area of inborn metabolic disorders.
White-matter disorders of unknown etiology constitute
a vexing problem in child neurology. Children with
neurological deﬁcits of central origin often demonstrate
white-matter abnormalities on magnetic resonance
(MR) imaging (MRI). Despite an extensive laboratory
work-up, 50% of these children remain without a
speciﬁc diagnosis (Kristjansdottir et al. 1996; van der
Knaap et al. 1999a). Both MRI and proton MR spec-
troscopy (MRS) have been used with success to identify
and deﬁne “new” disease entities among the children
with a leukoencephalopathy of unknown origin (Ha-
nefeld et al. 1993; Schiffmann et al. 1994; van der
Knaap et al. 1995, 1997, 2002, 2003; Leegwater et al.
2001a, 2001b). For this reason, we apply these tech-
niques systematically in the work-up of patients with
an unclassiﬁed leukoencephalopathy.
In 1999, we found highly elevated peaks in the sugar
and polyol region of the MR spectrum of a boy with leu-
Received December 1, 2003; accepted for publication January 20,
2004; electronically published February 25, 2004.
Address for correspondence and reprints: Dr.Marjo S. van der Knaap,
Department of Child Neurology, Vrije Universiteit Medical Center,
PO Box 7057, 1007 MB Amsterdam, The Netherlands. E-mail: ms
.vanderknaap@vumc.nl
 2004 by The American Society of Human Genetics. All rights reserved.
0002-9297/2004/7404-0015$15.00
koencephalopathy of unknown etiology (van der Knaap
et al. 1999b). The boy was born in 1984, the only child
of healthy, unrelated parents. He had psychomotor re-
tardation from early in life and developed epilepsy at age
4 years. From age 7 years, a slow neurological regression
occurred with prominent cerebellar ataxia, some spastic-
ity, optic atrophy, and a mild sensorimotor neuropathy.
Neither organomegaly nor dysfunction of the internal
organs was present. Extensive metabolic investigations
failed to reveal an underlying metabolic defect. MRI of
the brain at ages 11 years and 14 years showed extensive
abnormalities of the cerebral white matter (ﬁg. 1). Pro-
ton MRS of the brain revealed highly elevated abnormal
peaks, which could be identiﬁed as representing the pen-
titols ribitol and D-arabitol (ﬁg. 2). Quantitation of the
patient’s spectrum revealed a D-arabitol concentration
of 8.9 and a ribitol concentration of 2.9 mmol/liter of
white matter.
Polyols are sugar alcohols, subdivided on the basis of
C-atom number. For example, pentitols are polyols with
ﬁve C atoms. Numerous studies have shown that polyols
are present in human body ﬂuids (Jansen et al. 1986;
Kusmierz et al. 1989), but assessment of their levels is
not part of the general metabolic screening. We subse-
quently analyzed the levels of sugars and polyols in body
ﬂuids of the patient, using the method described by Jan-
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Figure 1 The transverse T2-weighted image of the brain, showing extensive abnormalities of the cerebral hemispheric white matter in
the patient (A), as compared with that of a normal individual (B).
Table 1
Sugar and Polyol Levels in Body Fluids of the Patient and Control Individuals
SUGAR
OR POLYOL
LEVEL (mmol/liter) IN CSF OF
LEVEL (mmol/liter)
IN PLASMA OF
LEVEL (mmol/mol creatinine)
IN URINE OF
Patient
( )np 3
Control Individuals
(aged 0–18 years)
Patient
( )np 5
Control Individuals
(aged 0–18 years)
Patient
( )np 3
Control Individuals
(aged 6–18 years)
Ribose 47–146 !5 !5 !5 !5–102 !5
Ribitol 891–1,249 !6 6–35 !5 123–186 !5–11
Arabinose 66–135 6–23 !5–7 !5 37–41 8–46
Arabitol 3,342–5,535 9–39 32–198 !5 1,021–1,612 16–89
Xylulose 88–166 !5 !5–10 !5 39–52 !5
Xylitol 33–96 !5 !5 !5 15–34 !5–7
Treitol 29–67 !7 !5–8 !5 38–81 7–83
Erythritol !5 12–33 !5 !5 20–49 35–179
Galactose !5 !5 !5 !5 !5–62 !5–18
Mannitol !5 !5 !5 !5 9–25 !5–74
Myoinositol 44–54 112–337 23–24 21–49 !5–8 !5–22
sen et al. (1986) and their reference ranges for urine. Ref-
erence values for sugars and polyols in plasma and cere-
brospinal ﬂuid (CSF) were determined in our laboratory.
The results of repeated analyses of urine, plasma, and
CSF of the patient are shown in table 1. Over the years,
ribitol and D-arabitol were consistently elevated in all
body ﬂuids. There was a high brain:CSF:plasma ratio
of 70:40:1 for D-arabitol and 125:55:1 for ribitol (van
der Knaap et al. 1999b). Decreased concentrations of
erythritol and myoinositol were found in urine and CSF,
whereas the concentrations of xylitol, xylulose, treitol,
arabinose, ribulose, and ribose were elevated (table 1).
The consistent abnormalities in the pentitol levels in
the present patient suggested a defect in their metabo-
lism. It is unfortunate that little is known about the meta-
bolic routes of polyols in humans. We hypothesized that
pentitols derive from their corresponding pentoses and
pentose phosphates, the latter being intermediates of the
pentose-phosphate pathway (PPP) (ﬁg. 3). We obtained
an additional piece of information when we identiﬁed a
patient with liver cirrhosis who also had elevated con-
centrations of ribitol, D-arabitol, and erythritol in urine
and plasma and in whom we could demonstrate a de-
ﬁciency of transaldolase, a major enzyme of the PPP, and
mutations in the related gene (Verhoeven et al. 2001).
We hypothesized that the present patient could also have
a defect in the PPP. We developed assays to study the
PPP enzymes xylulokinase, transaldolase, and transke-
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Figure 2 The ﬁrst and second rows show proton MR spectra of
cerebral white matter of the patient and a control individual, respec-
tively. The third and fourth rows show spectra of pure solutions of
50 mM D-arabitol and ribitol, respectively. The spectra on the left
were obtained with a short echo time (STEAM, repetition time 6,000
milliseconds, echo time 20 milliseconds); the spectra on the right were
obtained with a longer echo time (PRESS, repetition time 3,000 mil-
liseconds, echo time 135 milliseconds). The spectra of the patient and
the control individual were plotted on the same vertical scale to allow
a qualitative comparison. The spectra of the D-arabitol and ribitol
solutions were plotted on the same vertical scale. Note the high peaks
between 3.6 and 3.8 ppm in the short-echo-time spectrum of the pa-
tient, not present in the control individual. With a longer echo time,
a part of these peaks is below the baseline, related to so-called J-
coupling effects. D-arabitol and ribitol are represented by resonances
between 3.6 and 3.8 ppm. Comparing the short- and long-echo-time
spectra, the same effects of J-coupling are seen again, in particular in
D-arabitol. These data indicate that the resonances between 3.6 and
3.8 ppm in the patient can be ascribed to D-arabitol and, to a lesser
extent, ribitol. For further comments on the spectral changes in the
patient, see van der Knaap et al. (1999b). Ara p D-arabitol; Rib p
ribitol; Cho p choline-containing compounds; Cr p total creatine;
NAA p N-acetylaspartate; Lac p lactate; mIns p myoinositol.
tolase in erythrocytes and lymphoblasts, but we failed to
demonstrate a deﬁcient activity of any of those enzymes
in the patient.
We then developed a new sensitive method for mea-
suring intermediates of the PPP in blood spots (Huck et
al. 2003). This method can be used to study two addi-
tional enzymes of the PPP in cultured cell lines, ribose-
5-phosphate isomerase (RPI) (Enzyme Commission [EC]
number 5.3.1.6) and ribulose 5-phosphate epimerase
(RPE) (EC: 5.1.3.1).
In the PPP, ribulose 5-phosphate is converted both to
ribose-5-phosphate by RPI and to xylulose 5-phosphate
by RPE, providing the substrates for transketolase and
further conversion into glycolytic intermediates (ﬁg. 3).
To assay both RPI and RPE, we incubated ﬁbroblast ho-
mogenates with ribose-5-phosphate. Formation of the re-
action products ribulose 5-phosphate and xylulose 5-
phosphate was monitored using the new method based
on LC-MS/MS (API-3000 [Applied Biosystems]) (Huck
et al. 2003). For the enzyme assay, we used ﬁbroblast
homogenates of the patient and three control individ-
uals. The reaction was performed at 37C in a volume
of 300 ml, with concentrations of 45 mMTris HCl buffer
(pH 8.5), 21 mM Mg2, 0.1 mM thiamine pyrophos-
phate, and 4 mM ribose-5-phosphate (all from Sigma).
After taking 50-ml samples at 0 min, 30 min, and 120
min, sample clean-up was performed by adding 50 ml
5% perchloric acid, containing 5 mM stable isotope-la-
beled glucose 6-phosphate (internal standard), to the 50-
ml incubation samples and keeping the samples at20C
for 30 min. To neutralize the solution, 30 ml of 1 M
phosphate buffer (pH 11.5) was added, and the samples
were subsequently centrifuged for 5 min at 21,000g at
4C. After the supernatants were transferred to glass
vials, the samples were subjected to LC-MS/MS with an
ion-pair-loaded C18 high-performance liquid chromatog-
raphy column. Figure 4 shows the combined activities
of RPI and RPE in the patient and control individuals.
LC-MS/MS does not allow separate quantitation of the
reaction products ribulose 5-phosphate and xylulose 5-
phosphate. In contrast to the ﬁndings for control indi-
viduals, no increase in the combined ribulose 5-phos-
phate and xylulose 5-phosphate peak could be observed
in the patient, suggesting a deﬁciency of RPI.
An additional enzyme assay was developed to study
RPI separately. We incubated the same ﬁbroblast lines
with 6-phosphogluconate, which is a substrate for phos-
phogluconate dehydrogenase (EC: 1.1.1.44) and is con-
verted into ribulose 5-phosphate. Subsequent ribulose 5-
phosphate conversion to ribose-5-phosphate by RPI was
monitored by LC-MS/MS. The assay was performed at
37C in a volume of 3 ml of 100 mM Tris/HCl buffer
(pH 8.6), with concentrations of 33 mM 6-phosphoglu-
conate, 0.2 mM NAD, and 5 mM MgCl2. After taking
100 ml samples at 0 min, 30 min, and 120 min, clean-
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Figure 3 Schematic representation of the presumed reactions leading to the formation of the pentitols ribitol, D-arabitol, and xylitol
Figure 4 Combined activities of RPI and RPE in cultured ﬁbro-
blast homogenates, measured by monitoring the combined formation
of ribulose 5-phosphate and xylulose 5-phosphate from ribose-5-phos-
phate in three different control cell lines (unblackened bars) and in
three independent experiments in the patient cell line (blackened bars).
Results are expressed as the amount of the combined ribulose 5-phos-
phate  xylulose 5-phosphate formed during 2 h of incubation.Mean
values are given; error bars indicate the SD in the results of the control
cell lines.
up of the samples and sugar phosphate determination
was performed as described above. Formation of ribose-
5-phosphate by ﬁbroblasts, from the patient and the three
control individuals, during incubation with 6-phospho-
gluconate is shown in ﬁgure 5. A decreased formation
of ribose-5-phosphate could be observed in the patient as
compared with control individuals, again suggesting a
defect in RPI. Fifty percent of the expected ribose-5-phos-
phate was still produced when incubating the ﬁbroblasts
with 6-phosphogluconate, which could suggest residual
RPI activity. However, interconversions of pentoses also
may result in ribose-5-phosphate formation.
Because of the biochemical ﬁndings, we decided to
sequence the gene RPI. cDNA was synthesized from
total RNA derived from lymphoblasts of the patient by
Omniscript Transcriptase (RT) (Qiagen). The cDNA se-
quence of RPI has been published (Apel et al. 1995;
GenBank accession number NM_144563). RT-PCRs to
amplify RPI cDNA were performed using a set of RPI-
speciﬁc primers and Hot Startaq (Qiagen). Primer se-
quences will be provided on request. An automated DNA
sequencer (ABI 3100 [PE Biosystems]) was used to an-
alyze RPI cDNA, by use of BigDye terminator and cycle
sequencing (PE Biosystems). Sequence analysis of full-
length RPI cDNA demonstrated a single base-pair de-
letion (c.540delG) in the patient, causing a frameshift
change with asparagine 181 as the ﬁrst affected amino
acid and a shifted reading frame ending in a stop at
codon 17 (p.N181fsX17) (ﬁg. 6A). This predicts a trun-
cated protein of 196 amino acids. In addition, a single
transition, c.182CrT, was found, which leads to a sub-
stitution of alanine for a valine at codon 61 (p.A61V)
(ﬁg. 6B). The alanine at this position is conserved in the
Reports 749
Figure 5 RPI activity in cultured ﬁbroblast homogenates, mea-
sured by LC-MS/MS by monitoring the formation of ribose-5-phos-
phate from 6-phosphogluconate in three different control cell lines
(unblackened bars) and in three independent experiments in the patient
cell line (blackened bars). Results are expressed as the amount of
ribose-5-phosphate formed during 2 h of incubation. Mean values are
given; error bars indicate the SD in the results of the cell lines.
Figure 6 RPI cDNA sequence from a control lymphoblast sam-
ple and from the patient lymphoblast sample, showing a single base-
pair deletion (c.540delG) in exon 7 (A), resulting in a frameshift and
premature termination of translation of the RPI protein, and a single
transition, c.182CrT, in exon 4 (B), resulting in the substitution of
an alanine for a valine at codon 61 (p.A61V) in the RPI protein.
RPI of the two known species (mouse and rat). Direct
sequencing of PCR-ampliﬁed gDNA exon 4 and exon 7
of the patient conﬁrmed both the frameshift and the
missense mutations. The mother of the patient was found
to be heterozygous for the frameshift mutation. DNA
of the father was not available for investigation. These
mutations were not found in 220 control chromosomes
of individuals of Northern European descent, making it
unlikely that the mutations represent polymorphisms.
RPI deﬁciency is a novel inborn error in the PPP. The
most likely explanation for the biochemical abnormal-
ities in our patient is that deﬁcient conversion of ribulose
5-phosphate into ribose-5-phosphate leads to accumula-
tion of pentoses and pentose phosphates, which in turn
lead to accumulation of ribitol and D-arabitol as meta-
bolic end products. The elevated levels of pentoses found
in CSF and urine are in agreement with this. In normal
individuals, polyols are particularly abundant in the CNS
(Kusmierz et al. 1989; Shetty et al. 1995), suggesting
active production of polyols in nervous tissue or selective
transport toward the brain. These data may explain the
extreme accumulation of polyols in the nervous system
in our patient.
The disease is clinically characterized by a leukoen-
cephalopathy and mild peripheral polyneuropathy. The
extremely high levels of D-arabitol and ribitol in brain
tissue suggest that the leukoencephalopathy and neurop-
athy of the patient may be related to polyol toxicity. This
hypothesis is supported by the ﬁndings in two other dis-
orders. In diabetes mellitus and galactosemia, elevated
levels of the polyols sorbitol and galactitol are present,
and evidence has been provided that they may be im-
portant in the pathophysiology of the neurological dam-
age (Greene and Stevens 1996; Berry et al. 2001).
Peripheral neuropathy is a common complication of
diabetes mellitus, whereas cerebral white-matter abnor-
malities occur in galactosemia (Berry 1995; Sundkvist
et al. 2000). In nervous tissue of diabetic and galacto-
semic animals, accumulations of sorbitol and galactitol,
respectively, have been found (Sredy et al. 1991; Greene
and Stevens 1996), accompanied by a decrease in myo-
inositol. Evidence has been provided for a role of both
osmotic stress as a result of polyol accumulation (Kino-
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shita 1974) and defective Na/K-ATPase regulation as
a result of myoinositol depletion (Greene et al. 1988) in
the pathogenesis of nervous-tissue complications in dia-
betes mellitus and galactosemia.
The patient in the present study has leukoencephalo-
pathy, highly elevated ribitol and D-arabitol levels in his
brain and body ﬂuids, and a defect in the PPP (i.e., RPI
deﬁciency). Recently, we reported on a patient with liver
cirrhosis, abnormal polyol levels in her body ﬂuids, and
another defect in the PPP (i.e., transaldolase deﬁciency)
(Verhoeven et al. 2001). Our ﬁndings conﬁrm that defects
involving pentose and polyol metabolism constitute a new
area of inborn metabolic disorders, yet to be explored.
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